ADVM vs. DMAC, ELDN, INBX, PRQR, INMB, PBYI, OGI, PRME, ACIU, and IPHA
Should you be buying Adverum Biotechnologies stock or one of its competitors? The main competitors of Adverum Biotechnologies include DiaMedica Therapeutics (DMAC), Eledon Pharmaceuticals (ELDN), Inhibrx (INBX), ProQR Therapeutics (PRQR), INmune Bio (INMB), Puma Biotechnology (PBYI), Organigram (OGI), Prime Medicine (PRME), AC Immune (ACIU), and Innate Pharma (IPHA). These companies are all part of the "pharmaceutical products" industry.
Adverum Biotechnologies vs.
DiaMedica Therapeutics (NASDAQ:DMAC) and Adverum Biotechnologies (NASDAQ:ADVM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, community ranking, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.
DiaMedica Therapeutics has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, Adverum Biotechnologies has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500.
In the previous week, Adverum Biotechnologies had 6 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 20 mentions for Adverum Biotechnologies and 14 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 0.71 beat Adverum Biotechnologies' score of 0.12 indicating that DiaMedica Therapeutics is being referred to more favorably in the media.
DiaMedica Therapeutics' return on equity of -43.67% beat Adverum Biotechnologies' return on equity.
DiaMedica Therapeutics has higher earnings, but lower revenue than Adverum Biotechnologies. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks.
DiaMedica Therapeutics presently has a consensus target price of $8.00, indicating a potential upside of 95.03%. Adverum Biotechnologies has a consensus target price of $26.40, indicating a potential upside of 1,058.91%. Given Adverum Biotechnologies' higher probable upside, analysts clearly believe Adverum Biotechnologies is more favorable than DiaMedica Therapeutics.
Adverum Biotechnologies received 279 more outperform votes than DiaMedica Therapeutics when rated by MarketBeat users. However, 63.09% of users gave DiaMedica Therapeutics an outperform vote while only 60.26% of users gave Adverum Biotechnologies an outperform vote.
10.1% of DiaMedica Therapeutics shares are owned by institutional investors. Comparatively, 48.2% of Adverum Biotechnologies shares are owned by institutional investors. 7.3% of DiaMedica Therapeutics shares are owned by company insiders. Comparatively, 4.2% of Adverum Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
DiaMedica Therapeutics and Adverum Biotechnologies tied by winning 8 of the 16 factors compared between the two stocks.
Get Adverum Biotechnologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adverum Biotechnologies Competitors List
Related Companies and Tools
This page (NASDAQ:ADVM) was last updated on 5/21/2025 by MarketBeat.com Staff
Buy ADVM Stock Free ADVM Stock Alerts